GlycoNex is advancing a diversified pipeline across two complementary therapeutic modalities: innovative antibody-drug conjugates (ADCs) and biosimilars.
Rather than functioning as separate entities, these programs are integrated components of a unified growth strategy:
Innovative ADCs: Our glycan-directed ADCs pursue differentiated oncology targets — led by first-in-class GNX1021 — creating significant long-term value through scientific innovation.
Biosimilar Programs: These initiatives address large, established markets with well-defined regulatory pathways and durable patient demand.
Together, these capabilities allow GlycoNex to balance high-impact innovation with the commercial foundation, manufacturing expertise, and regulatory track record necessary to support sustainable, long-term growth.